MADDEN SECURITIES Corp Trims Holdings in Eli Lilly and Company (NYSE:LLY)

MADDEN SECURITIES Corp cut its holdings in Eli Lilly and Company (NYSE:LLY) by 0.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,616 shares of the company’s stock after selling 36 shares during the period. Eli Lilly and Company makes up 3.7% of MADDEN SECURITIES Corp’s portfolio, making the stock its 6th largest position. MADDEN SECURITIES Corp’s holdings in Eli Lilly and Company were worth $8,519,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in LLY. Capital Planning LLC bought a new stake in Eli Lilly and Company during the 1st quarter valued at $262,000. CHURCHILL MANAGEMENT Corp bought a new position in shares of Eli Lilly and Company during the first quarter valued at about $6,916,000. M&G Plc purchased a new stake in shares of Eli Lilly and Company during the first quarter worth about $8,896,000. HighPoint Advisor Group LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $9,878,000. Finally, Leo Wealth LLC purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $3,355,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 2.3 %

Shares of Eli Lilly and Company stock opened at $932.06 on Friday. The company has a 50-day simple moving average of $910.84 and a two-hundred day simple moving average of $852.32. The stock has a market capitalization of $885.83 billion, a PE ratio of 137.27, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LLY. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Guggenheim increased their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, September 16th. Finally, Berenberg Bank upped their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $979.29.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.